



OKLAHOMA STATE BOARD OF PHARMACY

An advisement emailed to Pharmacists and Pharmacies dated May 15, 2018 entitled "Pharmacies may resume the compounding of non-sterile medications for office use until further notice" was made in error due to a misinterpretation of an opinion from the U.S. Attorney General.

After recently receiving correspondence from FDA about compounding for office use, pharmacies that are not registered with the FDA as a 503B Outsourcing Facility may NOT compound any preparation for office use or hospital administration. This includes both sterile and non-sterile preparations.

All compounded preparations from a Pharmacy not registered as a 503B Facility must be compounded in compliance with the 503A Section of the F D & C Act.

This section mandates the compounded preparations must be for an identified individual patient based on the receipt of a valid prescription order that a compounded preparation is necessary for the identified patient.

The letter from FDA will be provided upon request to support this mandate. Please email request to pharmacy@pharmacy.ok.gov.

